生产企业：Heidelberg Pharma AG
HDP-103 is an Amanitin-based Antibody Drug Conjugate (ATAC) candidate developed by Heidelberg Pharma against metastatic castration-resistant prostate cancer. It has completed preclinical development and is available for partnering.
HDP-103 is an Amanitin-based Antibody Drug Conjugate (ATAC) candidate developed by Heidelberg Pharma against metastatic castration-resistant prostate cancer. It has completed preclinical development and is available for partnering.
HDP-103 is under development for the treatment of metastatic castration-resistant prostate cancer.
共 1 项相关疾病
